Chimeric Therapeutics Limited (ASX:CHM)
Australia · Delayed Price · Currency is AUD 0.0050
+0.0010 (25.00%)
Sep 25, 2026, 4:10 PM AEST
Chimeric Therapeutics Revenue
In the fiscal year ending June 30, 2026, Chimeric Therapeutics had annual revenue of -189.85K AUD. Chimeric Therapeutics had revenue of -2.81M in the half year ending June 30, 2026.
Revenue
-189.85K
Revenue Growth
n/a
P/S Ratio
-3.11
Revenue / Employee
n/a
Employees
n/a
Market Cap
590.64K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | -189.85K | -12.87M | - |
| Jun 30, 2025 | 12.68M | 5.23M | 70.09% |
| Jun 30, 2024 | 7.46M | 2.95M | 65.52% |
| Jun 30, 2023 | 4.51M | 1.89M | 72.16% |
| Jun 30, 2022 | 2.62M | - | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Acrux | 6.58M |
| Tissue Repair | 2.99M |
| Vectus Biosystems | 2.77M |
| Cynata Therapeutics | 1.71M |
| Bio-Gene Technology | 1.08M |
| Nexalis Therapeutics | 1.07M |
| Biotron | 525.87K |
| AdAlta | 404.25K |
Chimeric Therapeutics News
- 1 month ago - Chimeric Therapeutics Slides: Investor presentation - Filings
- 3 months ago - Chimeric Therapeutics Transcript: Study update - Transcripts
- 3 months ago - Chimeric Therapeutics Press release: Study update - Filings
- 5 months ago - Chimeric Therapeutics Transcript: EGM 2026 - Transcripts
- 6 months ago - Chimeric Therapeutics Transcript: NWR Virtual Healthcare Conference - Transcripts
- 6 months ago - Chimeric Therapeutics Slides: NWR Virtual Healthcare Conference - Filings
- 7 months ago - Chimeric Therapeutics Quarterly report: H1 2026 - Filings
- 11 months ago - Chimeric Therapeutics Transcript: Investor Update - Transcripts